Evidence map›Paper›PMID 31397957›Full record

ArticleJournal of cellular and molecular medicine2019

ST2 blockade mitigates peritoneal fibrosis induced by TGF-β and high glucose.

Yong Chul Kim, Kyu Hong Kim, Sunhwa Lee, Ji-Won Jo, Jae Yoon Park, Mi-Seon Park, Bodokhsuren Tsogbadrakh, Jung Pyo Lee, Jae Wook Lee, Dong Ki Kim and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Yong Chul KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Kyu Hong KimDepartment of Microbiology, The Ohio State University, Columbus, OH, USA.
Sunhwa LeeDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Ji-Won JoBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Jae Yoon ParkDepartment of Internal Medicine, Dongguk University Ilsan Hospital, Gyeonggi-do, Korea.
Mi-Seon ParkBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Bodokhsuren TsogbadrakhBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.
Jung Pyo LeeDepartment of Internal Medicine, Seoul National University Boramae Medical Center, Seoul, Korea.
Jae Wook LeeNephrology Clinic, National Cancer Center, Ilsan, Korea.
Dong Ki KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Kook-Hwan OhDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
In-Jin JangDepartment of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Korea.
Yon Su KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Ran-Hui ChaDivision of Nephrology, Department of Internal Medicine, National Medical Center, Seoul, Korea.
Seung Hee YangBiomedical Research Institute, Seoul National University Hospital, Seoul, Korea.ORCID 0000-0002-8575-6610
Seoul National University · KRSeoul National University Hospital · KRDongguk University Ilsan Hospital · KRNational Medical Center · KRThe Ohio State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal fibrosis (PF) is an intractable complication of peritoneal dialysis (PD) that leads to peritoneal membrane failure. This study investigated the role of suppression of tumorigenicity (ST)2 in PF using patient samples along with mouse and cell-based models. Baseline dialysate soluble (s)ST2 level in patients measured 1 month after PD initiation was 2063.4 ± 2457.8 pg/mL; patients who switched to haemodialysis had elevated sST2 levels in peritoneal effluent (1576.2 ± 199.9 pg/mL, P = .03), which was associated with PD failure (P = .04). Baseline sST2 showed good performance in predicting PD failure (area under the receiver operating characteristic curve = 0.780, P = .001). In mice with chlorhexidine gluconate-induced PF, ST2 was expressed in fibroblasts and mesothelial cells within submesothelial zones. In primary cultured human peritoneal mesothelial cells (HPMCs), transforming growth factor-β treatment increased ST2, fibronectin, β-galactosidase and Snail protein levels and decreased E-cadherin level. Anti-ST2 antibody administration reversed the up-regulation of ST2 and fibronectin expression; it also reduced fibrosis induced by high glucose (100 mmol/L) in HPMCs. Thus, high ST2 level in dialysate is a marker for fibrosis and inflammation during peritoneal injury, and blocking ST2 may be an effective therapeutic strategy for renal preservation.

Indexed as

AnimalsCells, CulturedDisease Models, AnimalEpithelial-Mesenchymal TransitionEpitheliumFemaleGlucoseHumansInterleukin-1 Receptor-Like 1 ProteinMaleMice, Inbred C57BLMice, KnockoutMiddle AgedPeritoneal DialysisPeritoneal FibrosisPeritoneumGlucoseIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 ProteinTransforming Growth Factor betaperitoneal dialysisperitoneal fibrosissoluble ST2ST2 blockade

Identifiers

PMID31397957
PMCPMC6787438
OpenAlexW2968972860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.